Clinical-Grade Waste Isolation Platform

Sever the Contamination
Cascade at the
Source.

Current absorbent garments act as biological incubators. DiviDiaper Inc. has engineered patented Waste Isolation Architecture that physically separates urine from stool—severing the pathway to IAD, CAUTI, and Sepsis. Because in critical care, a "standard" diaper is a clinical failure.

Join the Wefunder Round →

Patent-protected physical isolation technology

Clinician-endorsed by a world-leading pediatric urologist

INDA RISE Innovation Award — selected over major global manufacturers

Scroll

The Scale of the Problem

32-60%

Neonatal IAD Rates

Up to 60% of hospitalized neonates develop Incontinence-Associated Dermatitis (IAD)—a direct result of mixing waste streams against fragile skin.

150M

UTIs Annually

UTIs are a major global infection burden. In inpatient care, many are healthcare-associated driving avoidable treatment, length of stay, and complications.

75%

Of HA-UTIs are CAUTIs

~75% of healthcare-associated UTIs are catheter-associated (CAUTIs). Reducing catheter exposure pathways is a core infection-prevention priority.

$340M-$450M+

Annual CAUTI Costs

CAUTIs cost the U.S. healthcare system hundreds of millions annually, driving severe CMS penalties for preventable hospital-acquired infections.

The Clinical Reality

The Chemical Ignition:
Why Standard
Absorbency Fails

Traditional absorbent garments act as sponges, allowing urine and stool to mix into a toxic slurry directly against the patient's skin. This is not a hygiene problem; it is a rapid, biological chain reaction. Every step of this lethal cascade is clinically documented, and every step is preventable when you enforce physical isolation at the source.

The Pathogen Gateway

Enzymatic attacks dismantle the skin barrier, turning compromised tissue into a direct entry point for severe, hospital-acquired infections.

E. coli (Fecal Bacteria) Klebsiella Bacteria Proteus Bacteria Pseudomonas Bacteria Staph Bacteria Yeast Fungus

The Biology, Visualized

Diagram showing urine and stool mixing, ammonia release, pH shift from acidic to alkaline, and resulting damaged skin barrier

Diagram showing contamination pathway from urine/stool mixing through ascending UTI, pyelonephritis, bacteremia to urosepsis

The Biological Sequence — Step by Step

Urea meets Urease: The Chemical Ignition

The moment urine and stool mix, a biological chain reaction ignites. Fecal bacteria produce an enzyme called urease. When urease comes into contact with the urea present in urine, it rapidly breaks it down, liberating toxic ammonia. The local pH of the patient's skin immediately spikes from mildly acidic (protective) to strongly alkaline.

pH Disruption

Enzymatic Attack & Tissue Digestion

This alkaline pH environment is the exact trigger needed to hyper-activate fecal proteases and lipases (digestive enzymes from stool). These enzymes physically begin to digest the lipid and protein matrix of the patient's skin. The stratum corneum — the body's primary barrier — is chemically dismantled from the outside in.

Skin Barrier Failure

Incontinence-Associated Dermatitis (IAD)

This severe skin breakdown is clinically classified as IAD. It creates painful, weeping open wounds. For premature neonates in the NICU, post-surgical pediatric patients, or immunocompromised adults, this compromised tissue is no longer a protective barrier; it is an open door for pathogens.

IAD / Tissue Colonization

Catheter Biofilm Highway (The CAUTI Vector)

If a urinary catheter is present, fecal bacteria use the exterior of the tubing as a highway directly into the sterile bladder. They attach to the catheter surface and form complex biofilms — impenetrable microbial communities that can be 100 times or more resistant to standard antibiotic protocols than free-floating bacteria.

Catheter-Associated UTI

Systemic Escalation: Urosepsis

Once established, these biofilm-protected bacteria ascend from the bladder to the kidneys, causing severe Urinary Tract Infections. Left unchecked, the infection enters the bloodstream. This triggers Sepsis, a life-threatening systemic immune response. For infection-critical patients, the root cause of this fatal cascade wasn't the catheter; it was the failure to isolate waste in the garment.

Sepsis

The Waste Isolation Platform™

A Physical Firewall.
Separation by Design.

DiviDiaper Inc. engineers a new physical architecture into the absorbent garment. Our patented, soft, elasticized internal divider forms a complete seal against the perineum—urine stays in the front zone, stool stays in the back. When a catheter is present, our dedicated Catheter Containment Compartment physically isolates the tubing from the fecal zone, severing the contamination pathway before it starts.

Waste Isolation Test · Live Barrier Validation

Tap to Play

Barrier Confirmed — Live Test Footage

Liquid introduced into the anterior zone does not migrate across the internal divider into the posterior zone. Early-stage prototype tested by Bioana.

Catheter Containment Compartment · Architecture Demo

▶

Video Coming Soon

The Catheter Containment Compartment isolates the catheter port and tubing from the fecal zone — physically severing the primary contamination vector for catheter-associated UTIs.

Waste Isolation Platform — Deployed Under License

Two Clinical Brands.
One Patented Platform.

DiviDiaper Inc. operates on a single thesis: the absorbent garment is an untapped infection control tool. Harlows™ and Cathease™ are our proprietary clinical deployments—purpose-built to prove the Waste Isolation Platform™ in medical facilities, generate real-world outcomes data, and establish the standard that existing global manufacturers must license and adopt at scale.

Waste Isolation Platform™ · Divider Technology

Harlows™

DiviDiaper Inc.'s flagship pediatric brand establishes a zero-tolerance standard for neonatal skin failure. Harlows™ deploys our core divider technology to halt the pH cascade and enzymatic attacks in the NICU—replacing reactive wound treatments with absolute physical prevention.

NICU Neonates Post-Op Pediatric Medically Complex Infants

Waste Isolation Platform™ · CCC Technology

Cathease™

DiviDiaper Inc.'s CAUTI-focused deployment. Biofilms don't start in the bladder; they start in the garment. Cathease™ deploys the Catheter Containment Compartment (CCC) to physically sever the fecal-to-catheter pathway—removing the vector costing hospitals millions in CAUTIs and CMS penalties.

ICU / Critical Care Post-Surgical Adults Urological Patients

Where We Deploy

Built for the Environments
Where Failure is Fatal

The Waste Isolation Platform™ is designed for environments where contamination is most preventable, most visible in the data, and most expensive when things go wrong.

Priority Market

NICU & Pediatrics

Preterm and medically complex infants have fragile skin, immature immune systems, and long-term consequences from early infections. The Waste Isolation Platform™ physically interrupts the contamination cascade before neonatal skin is ever exposed — and protocols adopted in the NICU can become system-wide standards, making this the highest-leverage entry point for institutional adoption.

Surgical Recovery

Post-Surgical Care

Patients with incisions, drains, dressings, or stomas in the diaper area need protection from splash, seepage, and routine-change mishaps. The Waste Isolation Platform™ physically separates waste streams from the surgical field — protecting fresh stitches and fragile tissue without changing existing clinical workflow. A single contamination event can undo a successful procedure; the platform is engineered to prevent it.

CAUTI Prevention

Catheterized Patients

ICU, step-down, and long-term care patients face catheter-associated UTIs that drive length of stay, readmissions, and CMS penalties. The Waste Isolation Platform™'s dedicated Catheter Containment Compartment physically separates the catheter and tubing from the fecal zone — addressing the costly contamination vector at its source.

Traction & Validation

Built on Proof,
Not Projections

DiviDiaper has an active hospital deployment agreement with one of the most respected academic medical centers in the country, confirmed manufacturing viability at global scale, and won the nonwovens industry's most prestigious innovation award.

📋

Active Hospital Deployment Agreement

A formal 180-day agreement with a Major NYC Academic Medical Center — covering 1,500 units of Harlows™ in NICU infant sizes to generate real-world outcomes data. This is the gateway to system-wide institutional adoption.

🏥

Expert Clinical Endorsement

One of the world's leading pediatric urologists reviewed the DiviDiaper prototype and recognized its potential immediately — providing the expert endorsement that confirmed the architecture's real-world rationale.

🏭

Manufacturing Confirmed at Scale

A global leader in high-speed diaper machine manufacturing confirmed DiviDiaper's architecture runs on existing production lines via retrofit conversion kits. No new factories. No new supply chains. The infrastructure to produce at global scale already exists.

🏆

INDA RISE Award

Winner of the nonwovens industry's most prestigious innovation award — defeating major global manufacturers. Featured on FOX 5 New York.

The Investment Case

Weaponizing IP Against
Healthcare-Associated Infections

The absorbent hygiene market is massive, but structurally flawed. DiviDiaper's B2B licensing model allows us to scale our IP globally without the capital overhead of becoming a manufacturer.

🏥

Phase 1: Clinical Pilots

NICU and ICU pilots generate the undeniable clinical outcome data required to drive hospital system procurement decisions and validate the IP. The architecture is designed from day one to align with existing hospital supply chain reimbursement codes — removing the biggest institutional adoption barrier before the first conversation.

⚖️

Phase 2: Platform Licensing

We are built to license our patented Waste Isolation Platform™ — the divider architecture and Catheter Containment Compartment — to existing manufacturers, scaling from hospital supply chains into retail and home care channels globally.

💰

Phase 3: Institutional Scale

CAUTIs cost US hospitals hundreds of millions annually. CMS penalty programs make waste isolation a financial imperative for CFOs, not just clinicians. Our 'Retrofit-Ready' IP means we scale through existing global manufacturing lines—converting clinical proof into recurring revenue with zero capital expenditure.

The DiviDiaper Inc. Story

Born from a Surgical
"Hack" That Failed.

DiviDiaper Inc. started with two parents, one child, and a "standard of care" that left him completely exposed.

The Beginning

Harlow's Surgeries — and a System That Failed Him

Harlow Jeffers was born with hypospadias — a birth defect where the urethra exits on the underside of the penis rather than the tip. Correcting it required multiple reconstructive surgeries between ages one and three. Each surgery left fresh stitches, a urinary catheter, and weeks of careful recovery. The hospital's answer for post-op diapering wasn't a medical product — it was a workaround. Nurses would cut a hole through the front of one diaper, thread the catheter tube through it, then place a second diaper underneath to catch the urine. That was the standard of care.

The Moment

"If you have to hack it, it's broken."

One day, when Tivon went to change Harlow, stool had spread everywhere — right onto the fresh stitches on his scrotum. The hack had failed. In that moment, a question formed that became an invention. If a hospital has to "hack" a product to make it work, the product is broken. We decided to fix the product.

"What about a Divider?! What if we could separate the urine from the stool and keep it from reaching the surgical area?"

— Tivon Jeffers, Co-Founder & CEO

The Prototype

From Sketch to Physical Firewall

Tivon started sketching. Together with LisaRoxanne, they designed a diaper with a soft, internal elasticized divider — and when a catheter was present, a dedicated front compartment with a port for the tubing to exit cleanly. They built the first prototype and put it on Harlow. The front was wet. The back stayed dry. They tried again. The front held urine. The back held stool. Separated. No cross-contamination. It worked every time.

Original DiviDiaper concept sketch — W-Shaped Elastic Divider with Catheter Compartment

Clinical Recognition

A Surgeon Takes Notice. An Industry Follows.

They brought the prototypes to Harlow's surgeon, Dr. Dix Poppas — Chief of Pediatric Urology at NewYork-Presbyterian / Weill Cornell. He reviewed the prototype and recognized its clinical potential immediately, providing expert endorsement that validated both the design and its medical rationale. DiviDiaper Inc. was formally founded in New York, NY. Shortly after, it won the INDA RISE Innovation Award — beating out major global manufacturers. FOX 5 New York ran the segment: "Son's surgeries spur New York couple to invent new diaper."

"Just a better diaper that makes good sense — and should be used by all needing diapers."

— Dr. Dix Poppas, Chief of Pediatric Urology, NewYork-Presbyterian / Weill Cornell

Tivon and LisaRoxanne Jeffers receiving the INDA RISE Innovation Award

Today

From One Child to Every Patient

A globally recognized leader in high-speed diaper machine manufacturing confirmed the DiviDiaper design can run on existing production lines using retrofit conversion kits. No new factories required. The vision is clear: license the technology to existing global manufacturers so the divider protects patients everywhere — from the NICU to long-term care.

Industry Recognition

The Team

The People Behind
the Platform

A cross-disciplinary team of founders, operators, clinicians, and materials scientists — united by the belief that containment is a solvable engineering problem.

Leadership

Tivon Jeffers

Co-Founder & CEO

Hospital systems expert and entrepreneur whose firsthand experience navigating post-surgical care gaps drove him to rebuild the absorbent garment from the inside out. He leads DiviDiaper's clinical strategy, investor relations, and platform deployment.

LisaRoxanne Walters-Jeffers

Co-Founder & CLO

Attorney and entrepreneur with 20+ years in IP, compliance, and corporate law. A law professor and business founder, she co-invented DiviDiaper to drive innovation in healthcare.

Eugene Johnson

Chief Operating Officer

Operations and logistics leader with 20+ years building supply chains from the ground up. At DiviDiaper, he is architecting the infrastructure that will move the platform from clinical pilot to global manufacturing partnership.

A/Prof Bhavesh Patel

Clinical Advisor, Pediatric Surgery

Senior Pediatric Surgeon at Queensland Children's Hospital. Queensland Statewide Clinical Lead for Surgical Quality Improvement with 20+ years in pediatric/neonatal & urology surgery. Associate Professor and statewide medical educator.

John Poccia

Head of Nonwovens & Absorbent Materials

Former Johnson & Johnson leader holding 30+ U.S. patents. Spent decades advancing diapers, wipes, and medical products. Now guides DiviDiaper in scaling breakthrough absorbent technologies.

Community

This Mission Starts with People

Whether you're a NICU parent, a nurse, a caregiver, or someone who has lived the downstream consequences of a preventable infection — your story and your voice are part of why this platform exists.

Share Your Story

Have you experienced a NICU stay, a catheter-associated infection, or diaper-related complications? Your experience is part of the clinical case we're building.

💙

Thank You

Your story helps build the case for patients.

Send Us a Message

Questions about the platform, partnership interest, or media inquiries? Drop a message below. A real person reads every one.

✅

Message Sent

We'll be in touch within 2 business days.

Sever the ContaminationCascade at theSource.

The Chemical Ignition:Why StandardAbsorbency Fails